[author: Sherri Oslick]
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Janssen Products, L.P. et al. v. Hetero Drugs, Ltd., Unit III et al.
2:12-cv-03570; filed June 13, 2012 in the District Court of New Jersey
• Plaintiffs: Janssen Products, L.P.; Janssen R&D Ireland; G.D. Searle, LLC
• Defendants: Hetero Drugs, Ltd., Unit III; Invagen Pharmaceuticals, Inc.
Infringement of U.S. Patent No. RE42,889 ("α- and β-Amino Acid Hydroxyethylamino Sulfonamides Useful as Retroviral Protease Inhibitors," issued November 1, 2011) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of Janssen's Prezista® (darunavir, used to treat human immunodeficiency virus (HIV-1) infection). View the complaint here.